Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Seviteronel |
| Synonyms | |
| Therapy Description |
Seviteronel (VT-464) is a small molecule inhibitor of CYP17 17,20 lyase activity, resulting in decreased androgen production, which may inhibit growth of androgen-dependent tumors (PMID: 30012563, PMID: 25351916, PMID: 32327394). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Seviteronel | VT-464|INO-464 | Hormone - Anti-androgens 57 | Seviteronel (VT-464) is a small molecule inhibitor of CYP17 17,20 lyase activity, resulting in decreased androgen production, which may inhibit growth of androgen-dependent tumors (PMID: 30012563, PMID: 25351916, PMID: 32327394). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02580448 | Phase Ib/II | Seviteronel | A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer | Completed | USA | 0 |